Predictive and prognostic factors of gastric cancer
Authors:
D. Šmíd 1; D. Kubačková 1; J. Doležal 1; J. Fichtl 1; M. Pešta 2; V. Kulda 3; O. Daum 4; V. Třeška 1; T. Skalický 1
Authors‘ workplace:
Chirurgická klinika FN Plzeň a LF Univerzity Karlovy v Plzni
přednosta: prof. MUDr. V. Třeška, DrSc.
1; Ústav biologie LF Univerzity Karlovy v Plzni
vedoucí ústavu: RNDr. M. Pešta. Ph. D.
2; Ústav lékařské chemie a biochemie LF Univerzity Karlovy v Plzni
vedoucí ústavu: prof. MUDr. J. Racek, DrSc.
3; Šiklův ústav patologie FN Plzeň a LF Univerzity Karlovy v Plzni, Šiklův ústav patologie
vedoucí ústavu: prof. MUDr. M. Michal
4
Published in:
Rozhl. Chir., 2016, roč. 95, č. 4, s. 156-161.
Category:
Original articles
Overview
Introduction:
Gastric cancer is a frequent malignant disease with poor prognosis. Most patients undergo only palliative treatment. Chemotherapy is another alternative but its effect differs in individual patients.
Method:
This is retrospective study. We enrolled 54 patients (N=54) according to the inclusion criteria. We performed quantification of gene expression of selected genes and some microRNA from tumour tissue, which was used for the diagnosis. Statistical analysis of the data was performed.
Results:
We demonstrated a predictive value of gene expression of thynidylate synthase in tumour tissue for a therapeutic effect of chemotherapy based on 5-Fluorouracil or Capecitabine. At the same time, we demonstrated a predictive value of miR181, miR150, mir192 and miR342 microRNA levels from the tumour tissue. In addition, we succeeded to demonstrate a predictive value of miR221, miR224, miR520 and miR375 microRNA levels for a therapeutic effect of chemotherapy based on platinum derivates.
Conclusion:
Thanks to the use of efficient therapy predictors, we can distinguish those patients who will profit from chemotherapy from patients where an effect cannot be expected. Thanks to personified oncology therapy the quality of life of some patients can be improved while reducing the costs of the therapy by avoiding inefficient chemotherapy. Only an early diagnosis of gastric cancer can reverse the adverse prognosis of patients with this disease.
Key words:
gastric cancer – microRNA – prognostic markers – predictive markers
Sources
1. Krška Z, Chirurgická onkologie. Praha, Grada 2014.
2. Český statistický úřad – statistiky [on line]. Dostupný z: http://www.czso.cz.
3. Epidemiologie zhoubných nádorů v České republice [on line]. Dostupný z: www.svod.cz.
4. Waddell T, Verheij M, Allum W, et al. Gastric cancer ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014;40:584–91.
5. Šimša J. Karcinom žaludku. Praha, Maxdorf 2012.
6. Sasako M, Terashima M, Ichikawa W, et al. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer 2015;18:549.
7. Ross JB, Huh D, Noble LB, et al. Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol 2015;17:651–64.
8. El-Sedfy A, Dixon M, Seevaratnam R, et al. Personalized surgery for gastric adenocarcinoma: A meta-analysis of D1 versus D2 Lymphadenectomy. Ann Surg Oncol 2015;22:1820–7.
9. 9. Pesta M, Kulda V, Fiala O, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res 2012;32:5003–10.
10. Liu Y-P. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin‑based adjuvant chemotherapy. Oncol Lett [on line]. 2012 [cited 2015 Jul 8]; Available from: http://www.spandidos-publications.com/10.3892/ol.2012.1096.
11. Wang R, Wen H, Xu Y, et al. Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles. PloS One 2014;9:e113401.
12. Li Q, Wang JX, He YQ, et al. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 2014;5:e1197.
13. Tian S, Yu J, Kang W, at al. MicroRNA and gastric cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2014;36:214–7.
14. Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. WJG 2011;17:3976–85.
15. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010;46:298–311.
16. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM klasifikace zhoubných nádorů. 7. vydání, česká verze 2011. Praha, Ústav zdravotnických informací a statistiky ČR 2011.
17. NCCN clinical practice guidelines in oncology, gastric cancer, version I.2014 [on line]. Dostupný z: www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
18. Vyzula R, Modrá kniha České onkologické společnosti. Brno, Masarykův onkologický ústav 2014.
19. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593–600.
20. Liu YP, Ling Y, Qi QF, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett 2013;5:935–42.
21. Bosman F, Yan P. Molecular pathology of colorectal cancer. Pol J Pathol 2014;65:257–66.
22. Wang QX, Zhu YQ, Zhang H, et al. Altered MiRNA expression in gastric cancer: a systematic review and meta-analysis. Cell Physiol Biochem 2015;35:933–44.
23. Chen L, Yang Q, Kong WQ, et al. MicroRNA-181b targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. IUBMB Life 2012;64:628–35.
24. Katada T, Ishiguro H, Kuwabara Y, et al. MicroRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009;34:537–42.
25. Wang J, Liu S, Sun GP, et al. Prognostic significance of microRNA-221/222 expression in cancers: evidence from 1,204 subjects. Int J Biol Markers 2014;29:e129–41.
26. Jiang J, Zheng X, Xu X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PloS One 2011;6:e23271.
27. Kim JH, Jun KH, Jung H, et al. Prognostic value of preoperative serum levels of five tumor markers (Carcinoembryonic antigen, CA19-9, alpha-fetoprotein, CA72-4, and CA125) in gastric cancer. Hepatogastroenterology 2014;61:863–9.
28. Chen G, Zhang H, Xiao J, et al. Role of microRNAs in diagnosis and treatment of the pathogenesis of gastric cancer. Int J Clin Exp Med 2015 ;8:11862.eCollection2015.
29. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16–27.
30. Liu X, Chu KM. Circulating cell-free DNAs and miRNAs as promising non-invasive biomarkers for early detection of gastric cancer. Neoplasma 2016;63:1–9.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2016 Issue 4
Most read in this issue
- Skin and soft tissue infections (SSTIs)
- Splenosis as a rare cause of abdominal pain
- Kidney donors after circulatory death (DCD) – single centre experience
- Current status regarding surgical treatment of pancreatic cancer in the Czech Republic